Detectable vesicular stomatitis virus (VSV)–specific humoral and cellular immune responses following VSV–Ebola virus vaccination in humans

Journal article

In response to the Ebola virus (EBOV) crisis 2013-2016, a recombinant vesicular stomatitis virus (VSV)-based EBOV vaccine was clinically tested. A single-dose regimen of VSV-EBOV revealed a safe and immunogenic profile and demonstrated clinical efficacy. While EBOV-specific immune responses to this candidate vaccine have previously been investigated, limited human data on immunity to the VSV-vector are available. Within the scope of a Phase I study, we performed a comprehensive longitudinal analysis of humoral and cellular immune responses to internal VSV-proteins following VSV-EBOV immunization. While no pre-existing immunity to the vector was observed, up to 1/3 of subjects showed VSV-specific CTL-responses and antibodies.

Authors: Poetsch, J; Dahlke, C; Zinser, M; Kasonta, R; Lunemann, S

• Publication status: Published
• Peer review status: Peer reviewed
• Publisher: Oxford University Press
• Journal: Journal of Infectious Diseases
• Volume: 219
• Issue: 4
• Pages: 556–561
• Publication date: 2018-11-17
• Acceptance date: 2018-08-30
• DOI: 10.1093/infdis/jiy565
• EISSN: 1537-6613
• ISSN: 0022-1899
• Keywords: vaccine; Ebola virus; pre-existing immunity; VSV-EBOV; vesicular stomatitis virus; vector-immunity; V920